MyoStrain® Provides Comprehensive Assessment of Myocardial Deformation to Help Physicians Risk-Stratify Heart Failure Patients for Individualized Cardiac Treatment
- Dow ends at record high after upbeat jobless claims report
- PayPal (PYPL) Gains After Topping Q1 and Guidance Expectations, Crypto Seen as a Key Growth Driver Going Forward
- Square (SQ) Tops Q1 EPS by 25c
- Fed's Kaplan wants taper talk 'sooner rather than later'
- U.S. weekly jobless claims drop below 500,000; layoffs lowest since 2000
MyoStrain provided a uniquely sensitive and reproducible measure of segmental heart function to help physicians quantify differences in heart failure patients and risk-stratify patient populations based on the individual extent and severity of dysfunction
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
MORRISVILLE, N.C., April 19, 2021 /PRNewswire/ -- A new article published in the European Society of Cardiology (ESC) Heart Failure Journal demonstrated MyoStrain's ability to accurately detect and delineate patterns of myocardial dysfunction between heart failure (HF) types and severity.
Results showed that while traditional cardiac indices did not delineate myocardial dysfunction between patients, MyoStrain was able to successfully detect and differentiate myocardial function impairment among the different HF groups and the control group. MyoStrain also detected regional dysfunction occurring along the ventricular septum, even when left-ventricular ejection fraction was preserved, demonstrating MyoStrain's ability to discriminate between impaired and affected segments as they occur regionally throughout the myocardium.
Sebastian Kelle, MD, PhD, FSCMR, Head of Cardiac Imaging at the Berlin Center and the study's primary investigator, commented: "The study highlights the importance of using both longitudinal and circumferential strain to assess myocardial deformation in cardiac patients. This makes MyoStrain a critical tool for physicians to evaluate cardiac patients, as it uses both of these metrics in a single MyoHealth™ risk score. This information may help to guide individualized treatment decisions and potentially mitigate future dysfunction progression by monitoring the functional effects of treatment on the heart over time."
Full access to the publication is available here.
 Hashemi, D., et al. (2021) Myocardial deformation assessed among heart failure entities by cardiovascular magnetic resonance imaging. ESC Heart Failure, https://doi.org/10.1002/ehf2.13193
Media ContactAhmed OsmanPR@myocardialsolutions.com 919.802.6411
About Myocardial Solutions, Inc.Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI's proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
See original content: https://www.myocardialsolutions.com/news-article/myostrain-provides-comprehensive-assessment-of-myocardial-deformation-to-help-physicians-risk-stratify-heart-failure-patients-for-individualized-cardiac-treatment
View original content to download multimedia:http://www.prnewswire.com/news-releases/myostrain-provides-comprehensive-assessment-of-myocardial-deformation-to-help-physicians-risk-stratify-heart-failure-patients-for-individualized-cardiac-treatment-301271836.html
SOURCE Myocardial Solutions, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coronavirus Test Kits Market In North America- Abbott Laboratories, Becton, Dickinson and Co., Co Diagnostics Inc., among others to contribute to the market growth
- Suning International Showcases New One-Stop Solution for Overseas Brands to Enter China at the China International Consumer Products Expo
- Taaleri Plc’s Interim Statement 1 January–31 March 2021: Taaleri sold its wealth management operations and revised its strategy – a strong result in the first quarter
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Related EntitiesTwitter, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!